VKTX - バイキング・セラピュ―ティクス (Viking Therapeutics Inc.)

VKTXのニュース

   Viking Therapeutics to Present at Stifel Healthcare Conference 2020  2020/11/10 21:05:00 PR Newswire
SAN DIEGO, Nov. 10, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian,…
   Viking Therapeutics to Report Financial Results for Third Quarter 2020 on October 28, 2020  2020/10/21 20:05:00 PR Newswire
SAN DIEGO, Oct. 21, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for…
   Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK0214  2020/09/09 11:05:00 PR Newswire
SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 1 single ascending dose…
   Buy the Dip in Viking Therapeutics Stock, Says Analyst  2020/09/01 23:06:53 Yahoo Finance
Last week ended on a disappointing note for investors of NASH drug developer Viking Therapeutics (VKTX). Successive days in the red resulted in a cumulative share loss of 13%. The sell-off was instigated by two seemingly negative events.Firstly, Viking presented data from the Phase 2 study of VK2809
   Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress™ 2020  2020/08/28 10:00:00 PR Newswire
SAN DIEGO, Aug. 28, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of new results from the company's…
   Viking Therapeutics to Present at Stifel Healthcare Conference 2020  2020/11/10 21:05:00 PR Newswire
SAN DIEGO, Nov. 10, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian,…
   Viking Therapeutics to Report Financial Results for Third Quarter 2020 on October 28, 2020  2020/10/21 20:05:00 PR Newswire
SAN DIEGO, Oct. 21, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for…
   Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK0214  2020/09/09 11:05:00 PR Newswire
SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 1 single ascending dose…
   Buy the Dip in Viking Therapeutics Stock, Says Analyst  2020/09/01 23:06:53 Yahoo Finance
Last week ended on a disappointing note for investors of NASH drug developer Viking Therapeutics (VKTX). Successive days in the red resulted in a cumulative share loss of 13%. The sell-off was instigated by two seemingly negative events.Firstly, Viking presented data from the Phase 2 study of VK2809
   Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress™ 2020  2020/08/28 10:00:00 PR Newswire
SAN DIEGO, Aug. 28, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of new results from the company's…
   Viking Therapeutics to Report Financial Results for Third Quarter 2020 on October 28, 2020  2020/10/21 20:05:00 PR Newswire
SAN DIEGO, Oct. 21, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for…
   Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK0214  2020/09/09 11:05:00 PR Newswire
SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 1 single ascending dose…
   Buy the Dip in Viking Therapeutics Stock, Says Analyst  2020/09/01 23:06:53 Yahoo Finance
Last week ended on a disappointing note for investors of NASH drug developer Viking Therapeutics (VKTX). Successive days in the red resulted in a cumulative share loss of 13%. The sell-off was instigated by two seemingly negative events.Firstly, Viking presented data from the Phase 2 study of VK2809
   Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress™ 2020  2020/08/28 10:00:00 PR Newswire
SAN DIEGO, Aug. 28, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of new results from the company's…
   Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress™ 2020  2020/08/20 11:30:00 PR Newswire
SAN DIEGO, Aug. 20, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that data from the company's 12-week Phase 2 study of…

calendar